Endpoint innovation and success stories are driving a surge in renal disease drug development

As the most advanced FSHD programs aim to reduce muscle cell death, the next wave is targeting the disease’s genetic cause

A fall 2022 reset positioned an ADC for prostate cancer as the biotech’s top priority under new leadership

Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition

Travere aims to establish Filspari as standard of care in IgA nephropathy, even with the drug’s liver toxicity monitoring and restricted label

Plus: Erasca adds pan-RAF inhibitor from Novartis, and updates from UCB, Ambrx, Pharvaris and more 

King’s College spinout is inducing cardiomyocyte regeneration via nanoparticle-delivered miRNA

Plus China stocks rise again, Deepcell raises and updates from Qbic, AbbVie and more

BioCentury’s roundup of translational news

Pharma views Acceleron’s sotatercept as growth driver following Keytruda patent expiration